Raras
Buscar doenças, sintomas, genes...
Lesão pulmonar aguda
ORPHA:178320CID-10 · S27.3CID-11 · NB32.3DOENÇA RARA

É uma condição de dano pulmonar que se caracteriza pelo acúmulo de líquido nos dois pulmões (edema pulmonar), o qual é rico em neutrófilos (um tipo de célula de defesa). Isso ocorre na ausência de problemas cardíacos graves (insuficiência cardíaca). Pode apresentar diferentes tipos de lesões nos pulmões, tanto no revestimento dos vasos sanguíneos (endotelial) quanto nas células que revestem as vias respiratórias (epitelial), devido a diversos fatores (físicos, químicos ou biológicos).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma condição de dano pulmonar que se caracteriza pelo acúmulo de líquido nos dois pulmões (edema pulmonar), o qual é rico em neutrófilos (um tipo de célula de defesa). Isso ocorre na ausência de problemas cardíacos graves (insuficiência cardíaca). Pode apresentar diferentes tipos de lesões nos pulmões, tanto no revestimento dos vasos sanguíneos (endotelial) quanto nas células que revestem as vias respiratórias (epitelial), devido a diversos fatores (físicos, químicos ou biológicos).

Pesquisas ativas
4 ensaios
1410 total registrados no ClinicalTrials.gov
Publicações científicas
20.548 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: S27.3
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
6 sintomas
🫃
Digestivo
1 sintomas

+ 14 sintomas em outras categorias

Características mais comuns

55%prev.
Taquipneia
Frequente (79-30%)
55%prev.
Pneumonia
Frequente (79-30%)
55%prev.
Insuficiência respiratória
Frequente (79-30%)
55%prev.
Dispneia
Frequente (79-30%)
55%prev.
Infiltrados pulmonares
Frequente (79-30%)
55%prev.
Concentração elevada de proteína C-reativa circulante
Frequente (79-30%)
21sintomas
Frequente (11)
Ocasional (10)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 21 características clínicas mais associadas, ordenadas por frequência.

TaquipneiaTachypnea
Frequente (79-30%)55%
Pneumonia
Frequente (79-30%)55%
Insuficiência respiratóriaRespiratory failure
Frequente (79-30%)55%
DispneiaDyspnea
Frequente (79-30%)55%
Infiltrados pulmonaresPulmonary infiltrates
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico20.548PubMed
Últimos 10 anos200publicações
Pico2026198 papers
Linha do tempo
2026Hoje · 2026🧪 1987Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Lesão pulmonar aguda

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

1.410 ensaios clínicos encontrados, 4 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
11.210 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 11.210

#1

C3 as a sensitive biomarker of alveolocapillary barrier integrity in acute lung injury: Protective modulation by enoxaparin.

Tissue &amp; cell2026 Mar 19

Enoxaparin (ENX), a low-molecular-weight heparin (LMWH) widely used for venous thromboembolism prophylaxis, has been reported to inhibit complement activation at proximal steps. Early complement activation is increasingly recognized as a key driver of alveolocapillary barrier disruption, highlighting the need for early biomarkers and prophylactic strategies in ALI. Accordingly, this study investigated local and systemic effects of ENX on C2, C3, TNF-α, and IL-8 in an LPS-induced ALI model to clarify the contribution of complement blockade to inflammatory pathogenesis. Forty-six male Wistar albino rats were randomized in four groups (SHM, ENX, LPS, and ENX+LPS) and treated with intratracheal LPS (5 mg/kg) followed by subcutaneous ENX (2 mg/kg). After six hours, BALF, serum, and lung tissues were collected. Biomarkers were quantified by ELISA; histopathological changes were evaluated using staining (H-E, MT, PAS), and immunohistochemistry for TNF-α and CC16. LPS reduced serum C3, increased BALF TNF-α, enhanced TNF-α immunoreactivity, and disrupted the alveolocapillary barrier, reflected by elevated Smith and ATS scores. ENX mitigated these alterations, preserved barrier integrity, and restricted inflammation predominantly to the interstitium. Strong correlations between C3 levels and histopathological scores underscored its central role of C3 in the progression of ALI. Conversely, C2 showed limited variation and no correlation with tissue injury. CC16 expression was reduced following LPS exposure, indicating club cell dysfunction and interstitial inflammation, with only partial recovery under ENX. Collectively, these findings identify C3 as a sensitive early biomarker of complement-driven lung injury and support early complement modulation as a promising prophylactic approach in ALI.

#2

Efficacy of heparin in respiratory support of near-term rabbits with meconium-induced acute lung injury: Linear regression model analyses.

PloS one2026

To explore the pharmacotherapeutic efficacy of heparin in the management of meconium-induced acute lung injury (ALI) in near-term newborn rabbits subjected to mechanical ventilation (MV) and ancillary respiratory medications. Newborn rabbits at 30-day gestation (term 31 days) were anesthetized, intratracheally intubated and received human meconium-saline suspension, followed by parallel MV with individually adjusted tidal volume in a multi-plethysmograph-ventilator system. When ALI was induced after initial 3-h MV, therapeutic effects of single or combined subcutaneous heparin (100 U/kg), surfactant (200 mg/kg), and inhaled nitric oxide (iNO, 10 ppm), were compared for lung protective ventilation and survival as outcome, analyzed with linear regression models. Significantly reduced respiratory compliance by meconium was reinstalled during ensuing 7-h MV, with improved survival, among the treatment groups. The impact was verified by lung injury severity, surfactant phospholipid pools, and multiple mRNA expressions of surfactant proteins, lung fluid clearance-related factors, inflammatory mediators, growth factors, endothelial cell injury and coagulation-related factors as subphenotyping biomarkers. The overall benefits of heparin alone, or exerted with the dual and triple regimens, were discernible by both generalized linear model and Cox proportional hazard ratio regression for survival and other major variables as outcome. Its adverse effects were intangible. The comparable efficacy of heparin, alongside the PS and NO, was corroborated in attenuating meconium-mediated, ventilator-induced ALI, which should warrant clinical investigation to validate.

#3

Endogenous "Time Bomb" - Mislocalized Phospholipase A2 as a Critical Mediator of Ultra-Rapid Mortality in Sepsis and Acute Lung Injury.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 Mar 24

This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically within the alveolar environment to induce rapid, "electric shock-like" lethality, akin to chemical toxins, while also exhibiting extreme toxicity comparable to that of biological toxins, and functioning as a potential "time bomb" in the body. When exacerbated inflammation impairs the pulmonary barrier, PLA2 from the circulation can penetrate into the lungs. Once activated in the alveolar space, it rapidly hydrolyzes pulmonary surfactant phospholipids, causing a drastic decline in surface tension (>30%). This leads to alveolar overdistension, instantaneous respiratory failure, and asphyxiation-an acute mortality effect strikingly similar to that observed in sepsis and severe pulmonary diseases. PLA2 penetration and lethality are more pronounced in aged animals. Based on these findings, a combination therapy comprising phospholipase (dioleoylphosphatidylserine) and an inhibitor (varespladib) was developed, which significantly improved survival rates from 0% to over 90% in mice with sepsis, acute lung injury, and PLA2 poisoning. This study provides critical theoretical foundations and intervention strategies for the clinical treatment of related diseases.

#4

Prognostic significance of serum apelin-13 and galectin-3 concentrations as potential indicators of severity and mortality in pediatric acute respiratory distress syndrome.

The Turkish journal of pediatrics2026 Feb 27

The predictive and prognostic significance of apelin and galectin-3 as biomarkers in pediatric acute respiratory distress syndrome (PARDS) and lung injury has remained limited. This study examined the association between serum apelin-13 and galectin-3 levels, PARDS severity, and patient outcomes. The study included children aged 1 month to 18 years diagnosed with PARDS on admission to a pediatric intensive care unit, alongside age- and sex-matched outpatient controls. PARDS was diagnosed and classified by severity according to Second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) guidelines, based on oxygenation indices for non-invasive and invasive ventilation. Exclusion criteria included prior transplants, chronic lung disease, cyanotic congenital heart disease, prolonged ventilation, and other major conditions. After informed parental consent, 3 mL of peripheral venous blood was collected from all participants. Serum samples for apelin-13 and galectin-3 were stored at -80°C and analyzed using commercial enzyme-linked immunosorbent assay (ELISA) kits. Demographic, clinical, and laboratory data were systematically recorded for analysis. The study and control groups were comparable in age and gender. Patients had significantly lower hemoglobin, hematocrit, red blood cell, calcium, and phosphorus levels, and higher neutrophil counts, C-reactive protein, and liver enzymes. Apelin-13 levels did not differ significantly between groups, wheras median galectin-3 levels were significantly higher in patients (p=0.003). Apelin-13 levels were significantly lower and galectin-3 levels significantly higher with increasing PARDS severity. Severe PARDS was associated with lower PaO2/FiO2 ratios, arterial pH, and higher ventilator pressures. Mortality was 36.4% in severe and 22.7% in moderate PARDS. Serum galectin-3 level was the sole independent predictor of mortality (OR: 1.20, 95% CI 1.02-1.39, p=0.02). Although the apelin/APJ system's role in acute lung injury is known, its diagnostic and prognostic value in PARDS requires further study. Galectin-3 levels correlate with disease severity and outcomes, highlighting the need for larger, age- and phenotype-homogenized studies to confirm its role as an independent mortality predictor.

#5

Aerosolized adenoviral IL4/IL10 delivery alleviates LPS-induced acute lung injury.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2026 Mar 19

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory lung diseases with high morbidity and mortality, lacking specific treatments. Inhalation offers direct access to the damaged lung epithelium, making tracheal gene delivery a promising approach. However, challenges such as low efficiency, off-target effects, and repeated dosing limit its effectiveness. In this study, we developed an inhalable recombinant adenoviral vector (Ad-IL4/10) carrying dual reporter genes to deliver interleukin-10 (IL10) and interleukin-4 (IL4) to the lungs, enabling efficient and sustained expression of anti-inflammatory cytokines. Using a lipopolysaccharide (LPS)-induced lung injury mouse model, the anti-inflammatory effects of aerosolized Ad-IL4/10 were evaluated. The results showed that aerosolized Ad-IL4/10 significantly reduced weight loss, lung wet-to-dry weight ratio, and total protein levels in bronchoalveolar lavage fluid (BALF). Additionally, it alleviated pulmonary inflammation and alveolar damage while suppressing proinflammatory markers and LPS-induced monocyte and neutrophil infiltration. Ad-IL4/10 also restored monocyte-macrophage homeostasis. These findings indicate that an inhalable adenoviral vector effectively mitigates LPS-induced lung injury through IL4 and IL10 delivery, offering a promising therapeutic strategy for ALI.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC10.665 artigos no totalmostrando 196

2026

Harmine Derivatives Alleviate LPS-Induced Acute Lung Injury via Targeting GSK3β.

Inflammation
2026

EphA2 monoclonal antibody attenuates hyperoxia-induced acute lung injury by preserving the alveolar-endothelial barrier.

Scientific reports
2026

[Akt/SIRT3-dependent mitochondrial autophagy inhibits apoptosis of alveolar epithelial cells and alleviates hyperoxia-induced acute lung injury].

Zhonghua wei zhong bing ji jiu yi xue
2026

Immune-epithelial dual-targeting bilirubin nanoparticles for acute lung injury.

Journal of controlled release : official journal of the Controlled Release Society
2026

Modulation of the gut-lung axis by probiotic VSL#3 alleviates acute lung injury via restricting NETosis in sepsis.

Biochemical and biophysical research communications
2026

C3 as a sensitive biomarker of alveolocapillary barrier integrity in acute lung injury: Protective modulation by enoxaparin.

Tissue &amp; cell
2026

Efficacy of heparin in respiratory support of near-term rabbits with meconium-induced acute lung injury: Linear regression model analyses.

PloS one
2026

Efficiency of Alveolar Ventilation During High-Frequency Modes in Piglets: Effects of Airway and Tissue Heterogeneity.

Anesthesia and analgesia
2026

Endogenous "Time Bomb" - Mislocalized Phospholipase A2 as a Critical Mediator of Ultra-Rapid Mortality in Sepsis and Acute Lung Injury.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Cytokine-driven PANoptosis of alveolar macrophages mediated by STAT1 underlies acute lung injury in hypervirulent Klebsiella pneumoniae infection.

mBio
2026

Engineering Resatorvid-Loaded Sub-Microgels of Epigallocatechin-3-gallate/Hyaluronic Acid to Treat Acute Lung Injury.

Advanced healthcare materials
2026

Effect of reticulocalbin 3 on monocyte-to-macrophage differentiation in sepsis through modulating autophagy.

Chinese medical journal
2026

Autoantibodies induced by Mycoplasma pneumoniae infection underlie the severity of acute lung injury in children.

Mucosal immunology
2026

Prognostic significance of serum apelin-13 and galectin-3 concentrations as potential indicators of severity and mortality in pediatric acute respiratory distress syndrome.

The Turkish journal of pediatrics
2026

Plant-derived bioactive compounds attenuate acute lung injury by regulating cellular autophagy and inflammation: A review.

International immunopharmacology
2026

The CXCR2-XBP1-NF-κB Axis Drives Inflammatory Amplification and Tissue Damage in Acute Lung Injury.

Inflammation
2026

Lung-Selective Immune Reprogramming via In Situ Red Blood Cell Hitchhiking Nanoparticles.

bioRxiv : the preprint server for biology
2026

Serum Hepcidin Levels are Associated with Poor Outcomes of Patients with Severe Traumatic Brain Injury: A Two-Center Observational Analytical Study.

International journal of general medicine
2026

Ginsenoside Rg3 Mitigates LPS-Induced Injury in Human Bronchial Epithelial Cells by Restoring Autophagic Flux and Inhibiting the TLR4/NF-κB-Mediated Inflammatory Response.

Journal of inflammation research
2026

Predicting mortality with machine learning & biomarkers: A cohort analysis from aerosolized β₂-agonist for treatment of acute lung injury (ALTA) trial.

Physiological reports
2026

Nano-sized DNase scavenges cell-free DNA for acute lung injury treatment.

Journal of controlled release : official journal of the Controlled Release Society
2026

Phenylephrine attenuates LPS-induced lung injury via Foxh1/GSK-3β/β-catenin-mediated alveolar epithelial cell differentiation in ARDS.

International immunopharmacology
2026

A novel mechanism for treating acute lung injury with ligustilide: elucidation via network pharmacology and in vitro validation.

Journal of natural medicines
2026

Combined use of erythropoiesis-stimulating agents and transfusion guidelines in NICU infants.

Seminars in fetal &amp; neonatal medicine
2026

From canes to pills: the evolution of carbon monoxide therapeutics.

Advanced drug delivery reviews
2026

Aerosolized adenoviral IL4/IL10 delivery alleviates LPS-induced acute lung injury.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2026

Biomarkers in Traumatic Lung Injury - A Systematic Review.

The Journal of surgical research
2026

Curculigoside attenuates influenza virus-induced acute lung injury by modulating the Keap1/Nrf2 signaling pathway.

Naunyn-Schmiedeberg's archives of pharmacology
2026

Meis1-driven suppression of MIF/CD74 signaling promotes M2 macrophage polarization and protects against inflammatory damage in experimental acute lung injury.

Cell biology and toxicology
2026

Preformed HNA-3a antibodies in renal transplantation: A suggested approach to risk assessment.

Transplant immunology
2026

Atmospheric particulate matter impairs pulmonary barriers by triggering FTH1-mediated ferroptosis.

iScience
2026

Qingjin Pingchuan formula attenuates pulmonary inflammation by reprogramming neutrophil SHP1-JAK2/SRC-STAT3 signaling.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Microencapsulated Akkermansia muciniphila alleviates acute lung injury in juvenile mice by protecting intestinal barrier.

Frontiers in cellular and infection microbiology
2026

Mavacamten Derivatives Significantly Ameliorate Lipopolysaccharide-Induced Acute Lung Injury, Partly by Modulating Nuclear Factor Kappa‑B Signaling.

ACS pharmacology &amp; translational science
2026

Parabacteroides goldsteinii-derived outer membrane vesicles alleviate acute lung injury via modulation of bile acid metabolism.

Journal of nanobiotechnology
2026

Downregulation of Pannexin-1 attenuates sepsis-induced acute lung injury via activation of the cAMP/PKA pathway.

The international journal of biochemistry &amp; cell biology
2026

Spore-inspired surface engineering enhances macrophage phagocytosis for inhalation therapy of acute lung injury.

Journal of controlled release : official journal of the Controlled Release Society
2026

Comparative toxicity of menthol- and tobacco-flavored electronic cigarette constituents inducing inflammation, epithelial barrier dysfunction, and nicotinic acetylcholine receptor modulation in the absence of nicotine.

Toxicology reports
2026

Macrophage reprogramming and functional plasticity in sepsis.

Frontiers in immunology
2025

Blood Substitutes Used in Dentistry and OMFS: Systematic Review.

Journal of pharmacy &amp; bioallied sciences
2026

Triphenylphosphine bromide enhances the effect of nano-micellar drug delivery system loaded with ROS inhibitor TEMPO on acute lung injury.

Journal of biological engineering
2026

'Tripod-like' lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing.

Nature biomedical engineering
2026

Knowledge, attitudes, and practices regarding transfusion-related acute lung injury among healthcare providers in Jiangsu: a multicenter cross-sectional study.

Scientific reports
2026

Febrile transfusion-associated circulatory overload in adult oncology patients.

Vox sanguinis
2026

Design and synthesis of novel sEH inhibitors for the treatment of acute lung injury.

European journal of medicinal chemistry
2026

Unravelling the potential of Vitex negundo leaf extract in LPS-induced acute lung injury in mice through modulation of the TLR-4/NF-κB p65/iNOS pathway: Insights from integrated phytochemical characterization, in silico, and in vivo analysis.

Tissue &amp; cell
2026

Evaluation of Supracardiac Atherosclerosis in Stroke with a Noncontrast Head-Neck-Aortic Vessel Wall MRI.

Radiology
2026

High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.

The New England journal of medicine
2026

The Role of Duffy Antigen Receptor for Chemokines in Acute Respiratory Distress Syndrome.

Journal of leukocyte biology
2026

Lysine attenuates acute lung injury by restoring α-tubulin acetylation and ciliary activity.

Cell death discovery
2026

Exosomal Rspondin3 serves as a master regulator of immunometabolic repair in sepsis: synergistic activation of macrophage M2 polarization and endothelial BMP10 signaling.

International immunopharmacology
2026

LCN2 aggravates sepsis-induced ALI by inhibiting MUC1 to activate ER-stress-autophagy induced ferroptosis via lactate/MCT1/AMPK/mTOR axis.

Apoptosis : an international journal on programmed cell death
2026

The bug, the burden, and the biology: beyond host-centric phenotyping in sepsis.

The Journal of clinical investigation
2026

Inhaled bovine lactoferrin modulates the p47phox-MPO-NETosis axis in acute lung injury: implications for bioengineered nanomedicine in respiratory infections.

Frontiers in immunology
2026

Unbiased characterization of COVID-19 endotypes leads to prognostication of high-risk individuals using routine blood tests.

Communications medicine
2026

ASIC1a promotes alveolar epithelial apoptosis and acute lung injury through repression of the LncRNA00178/miR-466b-3p/Gucy1b1 ceRNA network.

International immunopharmacology
2026

Integrated Multi-Omics Analysis Reveals Modulation of the Ras Pathway by Siji Kangbingdu Mixture in Acute Lung Injury.

Combinatorial chemistry &amp; high throughput screening
2026

Telomere damage-mediated senescence in alveolar epithelial type II cells but not in macrophages aggravates inflammation in acute lung injury.

Respiratory research
2026

Biomimetic zwitterionic micelles for efficient mucus penetration and pulmonary targeting in acute lung injury.

Acta biomaterialia
2026

Post-Acute Sequelae of COVID-19 Persist Over 3 Years in Acute Lung Injury/Acute Respiratory Distress Syndrome Survivors But Are Not Associated With Persistent Thromboinflammation or Endothelial Dysfunction.

Critical care explorations
2026

Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury.

Circulation research
2026

USP19 alleviates LPS-induced acute lung injury via inhibiting TAK1 activation.

Biology direct
2026

Megakaryocyte and platelet thrombospondin-1 regulates matrix remodeling by stabilizing basement membrane COL6A1 in lung injury.

Nature communications
2026

FNDC4 modulates macrophage responses and suppresses NF-κB in sepsis-induced lung injury.

Molecular immunology
2026

Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment.

International immunopharmacology
2026

Protective Effects of Gallic Acid in LPS-Induced Lung Injury via Modulation of Oxidative Stress: AKT1/NRF2 and IL-10 Signaling.

Journal of biochemical and molecular toxicology
2026

Inhibition of macrophage pyroptosis protects against sepsis-induced injury to the alveolar epithelial barrier.

Journal of thoracic disease
2026

Intra- and extrapulmonary lipopolysaccharides-induced acute lung injury and pharmacotherapeutic response patterns in ventilated 7-day-old rabbits.

Experimental biology and medicine (Maywood, N.J.)
2026

Terminalia chebula Extract Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Modulating the Interleukin-17-Dependent Mitogen-Activated Protein Kinase/Nuclear Factor-Kappa B Signaling Pathways.

Phytotherapy research : PTR
2026

[Baicalin ameliorates obesity-related lung injury by targeting FSTL1/DIP2A signaling pathway].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
2026

Orthogonal NIR/Ratiometric Probe for Simultaneous Imaging of NO and ATP in Acute Lung Injury: Elucidating Metabolic Dysregulation and Therapeutic Screening.

Analytical chemistry
2026

Mechanistic insights into mitigation of sepsis-induced acute lung injury by quercitrin via TLR4/MAPK pathway inhibition.

The Journal of pharmacy and pharmacology
2026

Near infrared enhanced palladium loaded siraitia grosvenorii carbon dots amplify mitophagy for acute lung injury immunotherapy.

Bioactive materials
2026

Targeted inhibition of PARP-1 in pulmonary epithelial cells and macrophages via SPA-functionalized microparticles attenuates sepsis-induced lung injury.

Materials today. Bio
2026

Tetrastigma hemsleyanum Diels et Gilg Flavonoids Against Acute Lung Injury Via Block NLRP3 Inflammation.

Mediators of inflammation
2026

Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001-2023.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2026

Ginsenoside Rg1 mitigates sepsis-associated acute respiratory distress syndrome by promoting autophagy through the Prdx1-PTEN/PI3K/AKT pathway.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Nicotinamide N-oxide alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through activation of the SIRT1/AKT signalling pathway.

Pulmonary pharmacology &amp; therapeutics
2026

Phenolic fraction of Elsholtzia penduliflora W.W.Sm. ameliorates influenza A virus-induced acute lung injury by inhibiting the IDO-1-mitochondria-STAT1 signaling axis.

Journal of ethnopharmacology
2026

Therapeutic Effects Assessment in Acute Lung Injury Using Hyperpolarized 129Xe Magnetic Resonance.

NMR in biomedicine
2026

RANKL Attenuates Sepsis-Associated Acute Lung Injury Through the OPG/RANKL/RANK/TLR4 Pathway.

Immunity, inflammation and disease
2026

Circular RNAs in sepsis-induced acute lung injury: emerging mechanisms and therapeutic potential.

Frontiers in immunology
2026

Impact of optic nerve sheath diameter variations on respiratory mechanics in ventilated traumatic brain injury patients: A pilot prospective observational study.

Indian journal of anaesthesia
2026

Perfluorocarbon ameliorates high-altitude pulmonary edema and blood-gas barrier dysfunction in a canine model and a lung-on-chip model by suppressing the HIF-1α/HO-1 pathway.

European journal of pharmacology
2026

ERG-lacking endothelium identifies IL8-CXCR2 axis as a therapeutic target for resolving neutrophilic lung vascular injury.

JCI insight
2026

Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.

Materials today. Bio
2026

Polymyxin B-antioxidant nanoassemblies mitigate nephrotoxicity and attenuate sepsis-induced acute lung injury.

Journal of controlled release : official journal of the Controlled Release Society
2026

Mechanism of CircBbs9 in Lung Epithelial Cell Ferroptosis in Lipopolysaccharide-Induced Acute Lung Injury.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Contrast-Related Acute Pulmonary Edema Following Diagnostic Coronary Angiography: A Case Report.

Cureus
2026

LncRNA NORAD Enhances Inflammatory Injury in Sepsis-Associated Acute Lung Damage Through miR-150-5p/STAT1-Dependent NF-κB Activation.

The Kaohsiung journal of medical sciences
2026

Discovery of Peripherally Restricted Indazole-Based Phosphodiesterase 4B Inhibitors Targeting the C-terminal Regulatory Helix for Treating Acute Lung Injury.

Journal of medicinal chemistry
2026

KCNJ2-AS1 Drives Inflammation and Ferroptosis via the miR-212-3p/EGR1 Axis in Sepsis-Associated Acute Lung Injury.

Journal of biochemical and molecular toxicology
2026

Plasma Biomarkers of Brain Injury in Critically Ill Children Receiving Extracorporeal Membrane Oxygenation.

JAMA pediatrics
2026

Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.

Frontiers in pharmacology
2026

Molecular and Cellular Mechanisms Underlying the Therapeutic Effects of Genistein in Sepsis: A Systematic Review.

Journal of biochemical and molecular toxicology
2026

Association between ventilatory ratio and subsequent development of severe late acute kidney injury in acute respiratory distress syndrome.

Medicina intensiva
2026

Alveolar epithelial NF-κB/RelA guards the lung against bacterial infection.

Journal of immunology (Baltimore, Md. : 1950)
2026

PFKFB3-driven glycolysis in endothelial cells activates RhoA/ROCK1 to promote pulmonary vascular leakage in heatstroke.

Biochimica et biophysica acta. Molecular basis of disease
2026

The combination of paeoniflorin and hydroxysafflor yellow A alleviated pulmonary thrombosis by inhibiting platelet-neutrophil interaction via the P-selectin-PSGL-1 signaling axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Dysregulated Copper Metabolism-Induced Cuproptosis Contributes to Mitochondrial Dysfunction and Macrophage Inflammatory Response in Acute Lung Injury.

Antioxidants &amp; redox signaling
2026

Assessing the real-world drug safety of sevelamer for hyperphosphatemia: Insights from a comprehensive analysis of the FDA adverse event reporting system (FAERS) database.

Medicine
2026

Targeting the Keap1-Nrf2/GPX4 axis to suppress ferroptosis in acute lung injury.

Free radical biology &amp; medicine
2026

Protective effects of harringtonine on lipopolysaccharide-induced acute lung injury via a novel intratracheal instillation method.

International immunopharmacology
2026

Engineering Polymer-Lipid Integrated Nanoparticles with Quantitative Design Principles for Organ-Selective mRNA Delivery.

Journal of the American Chemical Society
2026

Fcer1g and St3gal1: Macrophage-associated angiogenesis biomarkers and therapeutic targets in sepsis-induced acute lung injury.

PloS one
2026

Microbial metabolite oxindole curbs acute lung injury by suppressing CXCL13.

Proceedings of the National Academy of Sciences of the United States of America
2026

Kidney-Lung Crosstalk in Acute Nephrologic Involvement: Mechanisms, Complement Activation, and Implications for Multiorgan Dysfunction.

Life (Basel, Switzerland)
2026

NETosis-Dependent Generation of Immunodeficient Low-Density Neutrophils Exacerbates Sepsis-Induced Acute Lung Injury.

International journal of molecular sciences
2026

Dietary Cannabis Seed Supplementation Attenuates Inflammation and Pancreatic Injury in a Cerulein-Induced Acute Pancreatitis Mouse Model.

Current issues in molecular biology
2026

Exploring the Effects and Mechanisms of Neohesperidin Dihydrochalcone on Acute Lung Injury in Mice with Sepsis Using Network Pharmacology and Machine Learning.

Current issues in molecular biology
2026

Oral and Intranasal Administration of Polydeoxyribonucleotide Isolated from Porphyra sp. Ameliorates Acute Lung Injury via Suppressing Proinflammatory Cytokine Production in Mice.

Current issues in molecular biology
2026

Extracellular Superoxide Dismutase in Acute Respiratory Distress Syndrome: Pathogenic Mechanisms and Therapeutic Implications.

Antioxidants (Basel, Switzerland)
2026

NEC-Associated Bronchopulmonary Dysplasia and the Gut-Lung Axis in Preterm Infants.

American journal of perinatology
2026

Platycodin D3 protects against sepsis-associated acute lung injury through direct inhibition of the PKM2-NLRP3 axis.

Cellular signalling
2026

The NLRP3 inhibitor, MCC950, attenuates environmental pollutant PM2.5-induced acute lung injury by inhibiting alveolar macrophage pyroptosis.

Current research in toxicology
2026

miRNA-149-5p protects endothelial function and attenuates sepsis-induced acute lung injury by targeting ABCA1.

International immunopharmacology
2026

Furin Inhibition Protects Against Acute Lung Injury in a Mouse Model of Pseudomonas Aeruginosa Infection.

American journal of respiratory cell and molecular biology
2026

ATP6V0C-HIF-1α reciprocal activation drives acute lung injury.

American journal of respiratory cell and molecular biology
2026

C-Type Lectin-Like Receptor 2 in Lung Epithelium Protects Against Acute Lung Injury.

American journal of respiratory cell and molecular biology
2026

Pulmonary atelectasis in anaesthesia and critical care.

BJA education
2026

1-Nitropyrene induces acute lung injury via SYVN1/Caspase-11-mediated apoptosis and pyroptosis in pulmonary epithelial cells.

Frontiers in pharmacology
2026

Novel Carbon Dots Nanomaterials for the Precision Diagnosis and Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome: Mechanisms and Applications.

International journal of nanomedicine
2026

N6-methyladenosine methylation in acute lung injury: Mechanisms and research progress.

Journal of intensive medicine
2026

Role of ITIH4 in Modulating YAP/TAZ-Mediated Apoptosis of Type II Alveolar Epithelium during Acute Respiratory Distress Syndrome.

Pharmaceutical research
2026

Role of ferroptosis and autophagy in pulmonary diseases.

Tissue &amp; cell
2026

Lactate regulation in high-altitude hypoxic adaptation attenuates LPS-Induced acute lung injury: links to glucose metabolism and anti-inflammatory therapeutic potential.

Critical care (London, England)
2026

FTY-720 pre-treatment attenuates acute lung injury following bilateral renal ischemia/reperfusion but not bilateral nephrectomy.

Scientific reports
2026

Discovery of 6l with a New Skeleton of 6-Oxo-N-(4-(Quinolin-4-yloxy)phenyl)-1,6-dihydropyridine-3-carboxamide as a Dual-Action Inhibitor against JNK2 and the MKK7-JNK2 Protein-Protein Interaction for Acute Lung Injury.

Journal of medicinal chemistry
2026

Agmatine suppresses the imidazoline I2 receptor/ribosomal S6 kinase 2/NF-κB signaling pathway regulating alveolar macrophage polarization and ameliorating sepsis-associated acute lung injury.

International journal of immunopathology and pharmacology
2026

Modified Dachengqi Decoction ameliorates sepsis-induced lung injury via the gut microbiota-bile acid axis.

Frontiers in cellular and infection microbiology
2026

Overcoming immune resistance in ovarian cancer: checkpoint inhibitors, tumor microenvironment, and translational advances.

Frontiers in oncology
2026

Farrerol mitigates lipopolysaccharide-induced acute lung injury through dual regulation of oxidative stress and inflammation via Nrf2 pathway.

Open life sciences
2026

The relationship between serum levels of miR-342 and miR-148a and acute lung injury in sepsis patients.

Open medicine (Warsaw, Poland)
2026

Monocyte-Derived Alveolar Macrophages in ALI/ARDS: The Core Drivers of Inflammation.

Immunology
2026

Cannabidiol mitigates secondary genital injury after thoracic trauma by regulating systemic inflammation and hormone receptor signaling.

Scientific reports
2026

Protective effects of dihydroartemisinin against sterile inflammation and oxidative stress in alveolar macrophages.

Biochimica et biophysica acta. General subjects
2026

Downregulation of RORα by alcohol promotes TGFβ and α-SMA expression in mouse lung fibroblasts.

Frontiers in medicine
2026

Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation.

Gut
2026

Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS.

BMJ open respiratory research
2026

Tanreqing injection regulates Sema7a/Plxnc1 signaling pathway mediated neutrophil extracellular trap formation to alleviate lipopolysaccharide-induced acute lung injury.

Journal of ethnopharmacology
2026

β-Hydroxy-β-methylbutyrate attenuates sepsis-associated lung injury by regulating NF-κB p65-mediated inflammation, ER stress and mitochondrial apoptosis in a rat model.

Naunyn-Schmiedeberg's archives of pharmacology
2026

Sorting nexin 10 knockdown: new strategies for alleviating sepsis-associated acute lung injury.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
2026

Retrospective Assessment of the Oxygenation Index in Dogs Undergoing Mechanical Ventilation for Primary Pulmonary Parenchymal Disease.

Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
2025

Xuanqing Hefa formula relieves sepsis-triggered acute lung injury by targeting the NLRP3/Caspase-1 pyroptosis mechanism.

Frontiers in immunology
2026

Fuzheng Jiedu Formula Ameliorates Acute Lung Injury by Modulating Gut Microbiota to Enhance Short-Chain Fatty Acid.

Journal of inflammation research
2026

Expert recommendations for setting and adjusting airway pressure release ventilation based on clinical experience and basic science evidence.

Frontiers in medicine
2026

Alexithymia in patients with posttraumatic stress disorder: A meta-analysis.

L'Encephale
2026

Polydatin attenuates LPS-induced acute lung injury in rats via targeting HSP90AB1.

Journal of ethnopharmacology
2026

Mitsugumin 53 protects against smoke inhalation lung injury via suppressing the proinflammatory response in a rat model.

Free radical biology &amp; medicine
2026

PKM2 from hyperactive neuron aggravate lung injury post-stroke by promoting FOXO3A/TXNIP mitochondria translocation in mice.

Redox biology
2026

MST1 modulates inflammation by inhibiting BNIP3 -dependent mitophagy via the JNK/p53 pathway in acute lung injury.

Tissue &amp; cell
2026

Limb remote ischemic preconditioning attenuates biomarkers of acute lung injury and inflammation during thoracoscopic lobectomy: a randomized controlled trial.

Clinics (Sao Paulo, Brazil)
2026

An immune-mediated effect of the antibiotic cefiderocol on LPS-induced acute lung injury.

Antimicrobial agents and chemotherapy
2026

Investigation of the Protective Effect of Stemona Alkaloids on Acute Lung Injury via LC-MS/MS-Based Sphingolipid Metabolomic Profiling.

Journal of mass spectrometry : JMS
2026

Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach.

Annals of transplantation
2026

An indoloquinolinone 3a alleviates lipopolysaccharide-induced acute lung injury by modulating the NF-κB and AMPK/Nrf2 signaling pathways.

International immunopharmacology
2026

Discovery of Chromone Derivatives as Selective BLT1 Inhibitors for Alleviating Acute Lung Injury and Sepsis.

Journal of medicinal chemistry
2026

Smart nebulized ROS-responsive hydrogel microspheres loaded with UC-MSCs-derived exosomes for the treatment of acute lung injury.

Materials today. Bio
2026

Digoxin attenuates LPS-induced acute lung injury in mice via NF-κB and HIF-1α inhibition.

Biomolecules &amp; biomedicine
2026

Targeting TRAF7: a new approach to modulate AKT in acute lung injury.

Science bulletin
2026

A multi-omics approach to decipher the protective mechanism of Myristica fragrans against acute lung injury.

Journal of ethnopharmacology
2026

Cepharanthine protects against lipopolysaccharide-induced acute lung injury in mice by blocking NLRP3 inflammasome activation.

International immunopharmacology
2026

Brain-derived neurotrophic factor and the derived dodecapeptide function as Toll-like receptor 4 antagonists in acute lung injury.

Nature communications
2026

β - sitosterol promotes the SUMOylation of DRP1 in alveolar macrophages and alleviates sepsis-associated acute lung injury.

Biochemical pharmacology
2026

Necroptosis mediated by FKBP5 in alveolar fibroblasts drives Pseudomonas aeruginosa-induced acute lung injury.

International immunopharmacology
2026

IFIT3 stabilizes STING via USP18 to drive M1 macrophage polarization and early inflammation in acute lung injury.

Cellular and molecular life sciences : CMLS
2026

Decoding the lncRNA-miRNA-mRNA network in sepsis-induced lung injury: from pathogenesis to extracellular vesicle-based therapy.

Frontiers in immunology
2026

The Novel Soluble Guanylate Cyclase Stimulator Attenuates Acute Lung Injury via Inhibiting Pericyte Phenotypic Transition.

International journal of molecular sciences
2026

Remimazolam alleviates acute lung injury by inhibiting ferroptosis: a multi-omics system pharmacology approach with experimental validation.

European journal of medical research
2026

Efficacy of sivelestat sodium for patients with acute lung injury and acute respiratory distress syndrome: a protocol for systematic review and meta-analysis.

Systematic reviews
2026

Sangbaipi Decoction mitigates influenza pneumonia in mice by inhibiting ZBP1-mediated PANoptosis.

Journal of ethnopharmacology
2026

Engineered CCR2 Cell Membrane-Wrapped Cepharanthine Liposomes for Potential Targeted Attenuation of Acute Lung Injury.

Cells
2026

Adipose Tissue-Derived Exosome and miR-142a-3p Alleviate Acute Lung Injury by Inhibiting HMGB1-Driven Autophagy.

Cells
2026

Involvement of Non-Muscle Myosin Light Chain Kinase Nitration in Molecular Regulation of Inflammation-Induced Endothelial Cell Barrier Dysfunction.

Cells
2026

A Novel Precision-cut lung slice stretch model using removable inflation materials.

bioRxiv : the preprint server for biology
2026

Platelet membrane-camouflaged matrine biomimetic nanoparticles for efficient acute lung injury therapy.

iScience
2026

Liang-Ge-San, a classic Chinese prescription, stimulates macrophage-secreted exosomal miR-21 to ameliorate lipopolysaccharide-induced acute lung injury through the regulation of PTEN/PI3K/AKT signaling.

Journal of natural medicines
2026

CPAP and high-flow nasal oxygen also reduce lung, diaphragm, and accessory muscle injury in experimental self-inflicted lung injury.

Scientific reports
2026

Multiomic analyses of longitudinal plasma samples identify thromboinflammation endotypes and trajectories in patients with trauma.

Science translational medicine
2026

Bibliometric Analysis of Published Articles on Acute Pancreatitis and Acute Lung Injury from 2004 to 2024.

Clinical laboratory
2026

Curcumin Attenuates Lipopolysaccharide-Induced Acute Lung Injury Through Anti-Inflammatory Effects in RAW Cells.

Chonnam medical journal
2026

Hypoxia-preconditioned mesenchymal stromal cell-derived exosomes attenuate LPS-induced acute lung injury and early epithelial remodeling in mice: evidence for a miR-486a-5p-Skp2-GATA4 axis.

Respiratory research
2026

NDRG1 aggravates Sepsis-Induced acute lung injury via PKM2-dependent activation of STAT3 and NF-κB signaling.

BMC immunology
2026

Ginkgetin alleviates sepsis-induced acute lung injury by promoting autophagy via inhibiting ubiquitination of Laptm5 in macrophages.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Secreted RCN3 acts as an early epithelial-fibroblast mediator via TGFβR1-Smad signaling in post-ALI pulmonary fibrosis.

Cell communication and signaling : CCS
2026

Interpretation of the efficacy-oriented components of decoction pieces in compounds based on the spectrum-effect relationship: Huangqin Qingfei decoction as an example.

Chinese medicine
2026

Machine Learning Approaches for Precision Risk Assessment of Transfusion Adverse Reactions: A Scikit-learn-Based Review.

Journal of visualized experiments : JoVE
2026

Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.

Discover nano
2026

650 nm red-light therapy attenuates sepsis-induced acute lung injury via adiponectin-mediated immune-metabolic reprogramming.

Frontiers in immunology
2026

Extracellular Vesicles Coordinate Bacterial Cloaking in Lung Epithelial Cells to Alleviate Acute Inflammatory Injury.

Journal of extracellular vesicles
2026

Endothelium-Treg Communication Through Extracellular Vesicle Transfer Exacerbates Acute Respiratory Distress Syndrome.

Journal of extracellular vesicles
2026

A macrophage-mimetic nanocarrier co-loaded with geraniol and FK13-a1 for MRSA-induced acute lung injury.

Drug delivery
2026

Intranasal curcumin mitigates paraquat-induced oxidative lung damage via involvement of neutrophil extracellular traps (NETs) in mice model.

Naunyn-Schmiedeberg's archives of pharmacology
2026

HU308, A Selective Cannabinoid Type-2 Receptor Agonist, Mitigates SARS-CoV-2 Spike Protein-Induced Acute Lung Injury in Mice.

Lung
2026

Phytotherapeutic potential of Bauhinia purpurea Linn. in hyperoxic lung injury: Insights from in vivo, network pharmacology and in silico analyses.

Journal of ethnopharmacology
2026

SIRT3-mediated mitophagy by deacetylating ATP5F1A involved in the protective effects of SIGMAR1/Sigma-1 receptor against ferroptosis and microvascular hyperpermeability in lipopolysaccharide-induced acute lung injury.

Autophagy
Ver todos os 10.665 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Lesão pulmonar aguda.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Lesão pulmonar aguda

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. C3 as a sensitive biomarker of alveolocapillary barrier integrity in acute lung injury: Protective modulation by enoxaparin.
    Tissue &amp; cell· 2026· PMID 41875697mais citado
  2. Efficacy of heparin in respiratory support of near-term rabbits with meconium-induced acute lung injury: Linear regression model analyses.
    PloS one· 2026· PMID 41875186mais citado
  3. Endogenous "Time Bomb" - Mislocalized Phospholipase A2 as a Critical Mediator of Ultra-Rapid Mortality in Sepsis and Acute Lung Injury.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)· 2026· PMID 41874474mais citado
  4. Prognostic significance of serum apelin-13 and galectin-3 concentrations as potential indicators of severity and mortality in pediatric acute respiratory distress syndrome.
    The Turkish journal of pediatrics· 2026· PMID 41871558mais citado
  5. Aerosolized adenoviral IL4/IL10 delivery alleviates LPS-induced acute lung injury.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences· 2026· PMID 41864520mais citado
  6. Kindlins in the cardiovascular system: from development to pathogenesis.
    Front Cardiovasc Med· 2026· PMID 41993866recente
  7. Attenuation of cGAS-STING signaling-mediated lung inflammation during infection through autophagy induction by bioactive nanodevices.
    Theranostics· 2026· PMID 41993619recente
  8. Atractylenolide II alleviates LPS-induced acute lung injury in A549 cells via the TNIP2/NF-κB pathway.
    J Cardiothorac Surg· 2026· PMID 41992343recente
  9. Transcriptomics and network pharmacology reveal that baicalin alleviates acute lung injury induced by H1N1 via targeting STAT1.
    Arch Microbiol· 2026· PMID 41989578recente
  10. Fecal microbiota transplantation alleviates sepsis-induced acute lung injury by improving mitochondrial function.
    Korean J Physiol Pharmacol· 2026· PMID 41991237recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:178320(Orphanet)
  2. MONDO:0015796(MONDO)
  3. GARD:20146(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q4677935(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Lesão pulmonar aguda
Compêndio · Raras BR

Lesão pulmonar aguda

ORPHA:178320 · MONDO:0015796
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
S27.3 · Outros traumatismos do pulmão
CID-11
Ensaios
4 ativos
Início
All ages
Prevalência
0.0 (Europe)
MedGen
UMLS
C0242488
Repurposing
1 candidato
sivelestatelastase inhibitor
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades